INT6065

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.74
First Reported 1992
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 15
Total Number 15
Disease Relevance 3.15
Pain Relevance 9.81

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (GRIN1)
Anatomy Link Frequency
dendrites 1
tendons 1
CB1 1
forebrain 1
interneurons 1
GRIN1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Glutamate 60 100.00 Very High Very High Very High
nMDA receptor 53 100.00 Very High Very High Very High
Dopamine 14 100.00 Very High Very High Very High
mu opioid receptor 9 100.00 Very High Very High Very High
agonist 16 99.88 Very High Very High Very High
allodynia 1 99.68 Very High Very High Very High
cocaine 18 99.56 Very High Very High Very High
Kinase C 1 99.36 Very High Very High Very High
Opioid 24 99.12 Very High Very High Very High
intrathecal 7 99.12 Very High Very High Very High
Disease Link Frequency Relevance Heat
Neuropathic Pain 1 99.68 Very High Very High Very High
Spasticity 1 99.16 Very High Very High Very High
Pain 10 99.12 Very High Very High Very High
Hyperalgesia 5 98.56 Very High Very High Very High
Dyskinesias 2 98.08 Very High Very High Very High
Convulsion 23 97.16 Very High Very High Very High
Amnesia 4 96.60 Very High Very High Very High
Inflammatory Pain 1 93.04 High High
Nociception 3 91.68 High High
Drug Dependence 2 90.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Glutamate NMDAR1 receptors localised to nerves in human Achilles tendons.
Localization (localised) of NMDAR1 in tendons associated with glutamate
1) Confidence 0.74 Published 2001 Journal Knee Surg Sports Traumatol Arthrosc Section Title Doc Link 11354854 Disease Relevance 0.41 Pain Relevance 0.69
Unprecedented developments in cannabinoid research within the past decade include discovery of a brain (CB1) and peripheral (CB2) receptor; endogenous ligands, anandamide, and 2-arachidonylglycerol; cannabinoid drug-induced partial and inverse agonism at CB1 receptors, antagonism of NMDA receptors and glutamate, and antioxidant activity; and preferential CB1 receptor localization in areas subserving spasticity, pain, abnormal involuntary movements, seizures, and amnesia.
Localization (localization) of NMDA in CB1 associated with pain, glutamate, convulsion, spasticity, nmda receptor, cannabinoid, amnesia and dyskinesias
2) Confidence 0.73 Published 1998 Journal Neurobiol. Dis. Section Abstract Doc Link 9974182 Disease Relevance 0.56 Pain Relevance 0.37
The drug has repeatedly been shown to be an antagonist at NMDAr, and our data suggested that its effects on spontaneous glutamate release were likely to be due to blockade of presynaptic facilitatory NMDA autoreceptors (see Berretta and Jones, 1996; Woodhall et al., 2001).
Localization (blockade) of NMDA associated with glutamate and antagonist
3) Confidence 0.73 Published 2010 Journal Neuroscience Section Body Doc Link PMC2877872 Disease Relevance 0.41 Pain Relevance 0.22
Taken together, these findings demonstrate that Neto1 is required for the normal abundance of synaptic NR2A-containing NMDARs and, as a result, for the normal contribution of NR2A-NMDARs to synaptic transmission and plasticity in CA1 hippocampus.


Localization (contribution) of NMDA in hippocampus associated with hippocampus
4) Confidence 0.73 Published 2009 Journal PLoS Biology Section Body Doc Link PMC2652390 Disease Relevance 0 Pain Relevance 0.09
Furthermore, NMDA receptor-mediated intracellular translocation and activation of PKC may be a critical step in the development of opioid tolerance.
Localization (translocation) of NMDA associated with nmda receptor, tolerance and opioid
5) Confidence 0.68 Published 1996 Journal Acta Anaesthesiol. Sin. Section Abstract Doc Link 9084551 Disease Relevance 0.18 Pain Relevance 1.76
Gender differences in kappa-opioid modulation of cocaine-induced behavior and NMDA-evoked dopamine release.
Localization (release) of NMDA associated with dopamine, opioid and cocaine
6) Confidence 0.68 Published 1998 Journal Brain Res. Section Title Doc Link 9729284 Disease Relevance 0 Pain Relevance 0.91
Prior in vivo cocaine administration did not alter the NMDA-evoked dopamine release.
Localization (release) of NMDA associated with dopamine and cocaine
7) Confidence 0.68 Published 1998 Journal Brain Res. Section Abstract Doc Link 9729284 Disease Relevance 0.09 Pain Relevance 0.94
Accordingly, we examined the effect of intrathecal SD-282, a selective p38 MAPK inhibitor, on NMDA-induced release of prostaglandin E(2) (PGE(2)) and thermal hyperalgesia.
Localization (release) of NMDA associated with thermal hyperalgesia and intrathecal
8) Confidence 0.68 Published 2003 Journal Neuroreport Section Abstract Doc Link 12821799 Disease Relevance 0.36 Pain Relevance 0.47
Eighty-four percent of 44 NMDAR-antibody-positive patients (as determined by the cell-based assay) precipitated EGFP-NR1 at levels greater than the mean plus three standard deviations (mean + 3SD) of results from 20 healthy controls (HCs).
Localization (precipitated) of EGFP-NR1
9) Confidence 0.57 Published 2010 Journal Brain Section Body Doc Link PMC2877907 Disease Relevance 0.13 Pain Relevance 0
The adverse effects of PCP on neurons were apparently not due to actions on N-methyl-D-aspartate (NMDA) receptors because: the neurons were not responsive to NMDA during the first 3 weeks in culture; concentrations of PCP that should block NMDA receptors maximally (1-50 microM) did not affect axon outgrowth or cell survival; and another NMDA receptor antagonist 2-amino-5-phosphonovaleric acid (APV) did not cause neurodegeneration or affect axon outgrowth.
Localization (block) of NMDA in neurons associated with nmda receptor antagonist and nmda receptor
10) Confidence 0.54 Published 1992 Journal Neuropharmacology Section Abstract Doc Link 1321358 Disease Relevance 0.16 Pain Relevance 0.18
Drugs targeting NMDA NR2B subunits in the forebrain could serve as a new class of medicine for controlling persistent pain in humans.
Localization (targeting) of NMDA in forebrain associated with pain and lasting pain
11) Confidence 0.43 Published 2002 Journal Drug Discov. Today Section Abstract Doc Link 11839523 Disease Relevance 0.46 Pain Relevance 0.76
There was a striking colocalization of MOR and NR1 labeling within dendrites.
Localization (colocalization) of NR1 in dendrites associated with nmda receptor and mu opioid receptor
12) Confidence 0.13 Published 1999 Journal J. Comp. Neurol. Section Abstract Doc Link 10340504 Disease Relevance 0.38 Pain Relevance 1.60
As an initial step to determine if proinflammatory activation of microglia might evoke release of NMDA-R agonists other than glutamate, we sought conditions suitable for detecting ligands of the glycine/D-serine site of the NMDA receptor.
Localization (release) of NMDA in microglia associated with glutamate, nmda receptor and agonist
13) Confidence 0.01 Published 2004 Journal J Neuroinflammation Section Body Doc Link PMC483052 Disease Relevance 0 Pain Relevance 0.43
Such disinhibition might be due to a direct blockade of NMDAr in interneurons and/or to a blockade of presynaptic, NMDA-dependent release of glutamate [46], [47].
Localization (release) of NMDA in interneurons associated with glutamate
14) Confidence 0.01 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2727800 Disease Relevance 0 Pain Relevance 0.39
The NMDA-induced hippocampal [(3)H]NA release was effectively blocked by the selective, non-competitive NMDA antagonist MK-801 (IC(50)=0.54 microM), indicating that the [(3)H]NA release was mediated through NMDA receptors.
Localization (release) of NMDA-induced associated with nmda receptor and antagonist
15) Confidence 0.00 Published 2009 Journal Neurochem. Int. Section Abstract Doc Link 19393275 Disease Relevance 0 Pain Relevance 1.01

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox